The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NVO | -52.28% | +53.5% | +8.94% | +41,664% |
| S&P | +11% | +85.61% | +13.15% | +5,007% |
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.
Semaglutide was no better than a placebo.
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $11.74B | 11.8% |
| Gross Profit | $8.94B | 1.1% |
| Gross Margin | 76.12% | -8.0% |
| Market Cap | $186.79B | -53.0% |
| Market Cap / Employee | $2.38M | -57.0% |
| Employees | 78.6K | 9.3% |
| Net Income | $3.13B | -22.1% |
| EBITDA | $4.94B | -7.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.05B | -40.8% |
| Accounts Receivable | $11.87B | 19.6% |
| Inventory | 7.5K | 31.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.04B | 82.2% |
| Short Term Debt | $1.89B | 129.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 21.83% | -5.2% |
| Return On Invested Capital | 55.78% | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $5.10B | 9.4% |
| Operating Free Cash Flow | $7.31B | 13.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 26.15 | 20.55 | 18.98 | 16.14 | -58.11% |
| Price to Book | 15.48 | 15.28 | 9.32 | - | |
| Price to Sales | 9.11 | 7.12 | 6.75 | 5.28 | -60.86% |
| Price to Tangible Book Value | 51.96 | 55.02 | 19.72 | - | |
| Price to Free Cash Flow TTM | 88.47 | 43.76 | 143.27 | 113.51 | 4.71% |
| Enterprise Value to EBITDA | 62.92 | 53.50 | 54.88 | 52.13 | -47.60% |
| Free Cash Flow Yield | 1.1% | 2.3% | 0.7% | 0.9% | -4.50% |
| Return on Equity | 82.0% | 87.5% | 75.9% | 68.3% | -22.56% |
| Total Debt | $14.27B | $17.19B | $15.62B | $15.93B | 86.79% |
NVO earnings call for the period ending December 31, 2024.
NVO earnings call for the period ending September 30, 2024.
NVO earnings call for the period ending June 30, 2024.
NVO earnings call for the period ending March 31, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
